FDA Approval Alert: The Need-to-Know | Toripalimab for Recurrent/Metastatic Nasopharyngeal Carcinoma

In October 2023, the FDA approved frontline toripalimab-tpzi plus cisplatin and gemcitabine for adult patients with metastatic or locally advanced nasopharyngeal carcinoma, as well as single-agent toripalimab for recurrent, unresectable, or metastatic disease that has progressed on or following prior chemotherapy.

Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Expert Discusses Safety of Toripalimab in Advanced Nasopharyngeal Carcinoma
Video
Jan 24, 2024 1:00 PM
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Toripalimab Yields ‘Striking’ PFS Improvement in Nasopharyngeal Carcinoma
Video
Jan 19, 2024 1:00 PM
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.
FDA Approves Toripalimab for Recurrent/Metastatic Nasopharyngeal Carcinoma
Article
Oct 27, 2023 8:32 PM
Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.